Cargando…

Minimal residual disease (MRD) in the bone marrow in ER-α-positive primary breast cancer patients

Detalles Bibliográficos
Autores principales:	Coombes, RC, Bella, MT De, Tripuraneni, G, Zaidi, A, Anwer, S, Stephens, DA, Ward, B, Sinnett, HD, Slade, MJ
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4231892/ http://dx.doi.org/10.1186/bcr1212

Ejemplares similares

Editorial: Minimal residual disease (MRD) assessment in multiple myeloma patients
por: Maiolino, Angelo, et al.
Publicado: (2023)

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
por: Kuiper, Roland P., et al.
Publicado: (2021)

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
por: Cumbo, Cosimo, et al.
Publicado: (2020)

Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)
por: Nagafuji, Koji, et al.
Publicado: (2013)

A Cost Impact Analysis of clonoSEQ(®) as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in Germany
por: Walzer, Stefan, et al.
Publicado: (2021)

Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
por: Peng, Yan, et al.
Publicado: (2021)

S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL
por: Russell, Nigel, et al.
Publicado: (2023)

Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia
por: Othus, Megan, et al.
Publicado: (2016)

Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
por: Larribère, Lionel, et al.
Publicado: (2021)

Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review
por: Zhu, Lemei, et al.
Publicado: (2023)

Minimal residual disease assessment in acute lymphoblastic leukemia by 4-color flow cytometry: Recommendations from the MRD Working Group of the Brazilian Society of Bone Marrow Transplantation
por: Ikoma-Colturato, Maura R.V., et al.
Publicado: (2021)

Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
por: Fonseca, Rodrigo, et al.
Publicado: (2023)

Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment
por: Slade, M J, et al.
Publicado: (2009)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma
por: Medina, Alejandro, et al.
Publicado: (2020)

Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
por: Fonseca, Rodrigo, et al.
Publicado: (2023)

Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma
por: Bansal, Radhika, et al.
Publicado: (2023)

Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies
por: Thompson, Philip A., et al.
Publicado: (2018)

PB2149: MINIMAL RESIDUAL DISEASE (MRD) DETECTION TRENDING AS A PRIMARY ENDPOINT IN CERBA RESEARCH MULTIPLE MYELOMA (MM) TRIALS
por: Gaspo, Rania, et al.
Publicado: (2023)

S203: QUADRUPLET INDUCTION THERAPY, ASCT AND MRD-MODULATED CONSOLIDATION AND TREATMENT CESSATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA: FINAL ANALYSIS OF THE MASTER TRIAL
por: Costa, Luciano, et al.
Publicado: (2023)

Measurable Residual Disease (MRD) as a Surrogate Efficacy-Response Biomarker in AML
por: Meddi, Elisa, et al.
Publicado: (2023)

Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR)
por: Weber, Axel, et al.
Publicado: (2012)

Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)—Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)
por: Chakrabarti, Sakti, et al.
Publicado: (2022)

P360: MEASURABLE/MINIMAL RESIDUAL DISEASE (MRD) STATUS IS THE MOST RELEVANT INDICATOR OF CLINICAL OUTCOME IN MIXED PHENOTYPIC ACUTE LEUKEMIAS (MPAL)
por: Tembhare, Prashant, et al.
Publicado: (2023)

PB1806: ULTRA-SENSITIVE MINIMAL RESIDUAL DISEASE (MRD) MONITORING FOR LEUKEMIA PATIENTS USING SUPERRCA MUTATION ASSAYS WITH FLOW CYTOMETER READOUT
por: Chen, Lei, et al.
Publicado: (2023)

S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL
por: Urban, Aleksandra, et al.
Publicado: (2023)

Role of peripheral blood MRD and 18F-FDG PET in the post-CAR relapse setting: a case study of discordant peripheral blood and bone marrow MRD
por: Schultz, Liora, et al.
Publicado: (2023)

FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD)
por: Lo Nigro, Luca, et al.
Publicado: (2022)

Evaluation of CD30 expression in B ALL and its correlation with MRD(Minimum Residual Disease)
por: Kazemian, Amirhossein, et al.
Publicado: (2021)

Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication
por: Tiong, Ing S., et al.
Publicado: (2023)

411 Mrd. €, 11,9 %
por: Kuhn, Joseph
Publicado: (2022)

S115: CONSOLIDATION WITH BLINATUMOMAB IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF AGE AND MRD LEVEL IN ECOG-ACRIN E1910
por: Litzow, Mark, et al.
Publicado: (2023)

Quality Assessment for PCR-based Minimal Residual Disease in Lymphoma: 10 Years of Cross-laboratory Standardization Process Within the Fondazione Italiana Linfomi MRD Network
por: Mantoan, Barbara, et al.
Publicado: (2021)

PB2443: APPLICABILITY OF SHORT TANDEM REPEAT (STR) IN LEUKEMIA PATIENTS RECEIVED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THE ERA OF MINIMAL RESIDUAL DISEASE (MRD)
por: Kim, Juhyung, et al.
Publicado: (2023)

Targeting estrogen to kill ER-positive and ER-negative breast cancer
por: Jordan, VC
Publicado: (2005)

S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL
por: Kater, Arnon, et al.
Publicado: (2023)

Detection of gene amplification in matched tumour and plasma DNA from breast cancer patients by quantitative PCR
por: Page, K, et al.
Publicado: (2008)

P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION
por: Jentzsch, Madlen, et al.
Publicado: (2023)

MRD in AML: The Role of New Techniques
por: Voso, Maria Teresa, et al.
Publicado: (2019)

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year
por: van der Linde, Riana, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ce0c9svalo1u00ol322e1t0ulf